SlideShare una empresa de Scribd logo
1 de 15
Pros & cons of eCTD baseline
        submissions
What is a baseline submission?

   Single eCTD submission capturing all the appropriate
  information that
  reflects what has been submitted
   oAll modules
   oModule 3 only (32S, 32P, 32A and/or 32R)
  Corresponds to approved marketing license of a drug
  Merges per eCTDs per strength to single eCTD lifecycle




20110920                   Pros & cons of baseline submissions   2
Content of a baseline

   Module 1
  Cover letter (state content has not changed, only its format)
   Module 2
  Integrated overviews and summaries for Quality, Nonclinical and
   Clinical or a clear combination of those
  Cumulative list of all clinical trials
  Individual study synopses
   Module 4 + 5
  All study reports as is
20110920                     Pros & cons of baseline submissions     3
Content of a baseline

   Module 3
  No chronological cumulative presentation, but a “current view”
  Hyperlinks not necessary
  Do not
   oExclude any information form original dossier (unless updated by
    a regulatory process)
   oInclude any information not submitted before in the original dossier
  Document granularity that fits best
   with the lifecycle of documents                         Granularity!?


20110920                    Pros & cons of baseline submissions            4
Document granularity Module 3

  Coursest and finest granularity defined by ICH M4 on
  organisation of Module 3
   Determine granularity based on likelihood of:
  Future changes
  Reusability across products
  Reusability across regions
   Apply meaningful names for now, here and the future
                Subsequent sequences should match
              granularity of the previous sequences

20110920                   Pros & cons of baseline submissions   5
Granularity and future?

  Only replace or delete whole documents, not sections or
  pages in eCTD
  e.g. single 32P33 vs. Formulation, filling, packaging and labelling
   Mention information only once and in a single document
  e.g. Batch numbering in 32P33 only and not repeated in 32P54
   Do not mention the reason for submitting a document
  e.g. Do not mention “to support the change of.....”



20110920                    Pros & cons of baseline submissions          6
Granularity and regional difference

  Additional specifications beyond the Ph.Eur. in a subset
  of countries
  S41 Specifications Ph.Eur. Vs. S41 Specifications polymorphism
   Different level of detail in a limited number of documents
  e.g. Details around control of critical steps, whereas the remainder
   is identical




20110920                    Pros & cons of baseline submissions           7
Granularity and reuse across products

   Separate content from context
  Drug substance documentation not refering to the context of use
  Analytical procedures across substances and products
  P1 Description and composition vs. Container description
  P4 Compendial combined vs. Compendial individual
  P7 Container material information, rather usage




20110920                   Pros & cons of baseline submissions       8
How to define the granularity?

   By use of an ToC outline capturing granularity and naming
             Analytical procedure “Test C by Method D” is not
            product specific and can be reused across products




20110920                     Pros & cons of baseline submissions   9
When to be created and submitted?

   At start of an eCTD lifecycle for an existing dossier
  0000=Baseline
  0001=Major variation or renewal




   During the eCTD lifecycle



20110920                  Pros & cons of baseline submissions   10
Pros of baseline submissions

  Ability to remove repeating and therefore redundant
 information, such as
 Scale at other sections than S22 and P33
 Manufacturer names at other sections than S21, P31 and A1
 Buildings at other sections than A1
  Ability to create content in context in appropriate sections
 Manufacturing process development and Pharmaceutical development
  Ability to apply specific information at relevant sections only
 In text and in header and footer
20110920                   Pros & cons of baseline submissions       11
Pros of baseline submissions 2

   Ability to start a clear lifecycle and audit trail
   Ability to create documents for reuse across products, e.g.
  Filling, packaging and labelling processes
  Selection and justifications for excipients
  Suitability of container
  Excipients
  Analytical procedures (and Quality by design)
  Container closure systems
  Facilities and equipment
20110920                   Pros & cons of baseline submissions   12
Pros of baseline submissions 3

   Greatly improves the review process
  Within the company
  For agencies
   Improves transparency
  What document has been submitted where?
  What products are supported by a document?
  EU agencies encourage/recommend baseline
  submissions; US accepts these

20110920                 Pros & cons of baseline submissions   13
Cons of baseline submissions

   Time consuming (up to 15 days)
  Requires limited content knowledge and advanced Word knowledge
   Insufficiencies and incompliance becomes apparent; e.g.
  Lack of validation because it got approved before it was required
  Lack of stability data because it was OK at time of registration
   Inability to
  Add more recent though never submitted information
  Correct erroneous information
  Remove out-dated though never replaced information
20110920                    Pros & cons of baseline submissions        14
Thank you




www.ectdconsultancy.com

Más contenido relacionado

La actualidad más candente

Regulatory submission in Japan
Regulatory submission in JapanRegulatory submission in Japan
Regulatory submission in JapanRohit Patil
 
Electronic Submissions
Electronic SubmissionsElectronic Submissions
Electronic Submissionsshakulbio
 
NDA Application.pptx
NDA Application.pptxNDA Application.pptx
NDA Application.pptxVenugopal N
 
A PRESENTATION ON DOSSIER.pptx
A PRESENTATION ON DOSSIER.pptxA PRESENTATION ON DOSSIER.pptx
A PRESENTATION ON DOSSIER.pptxanku4sin
 
Variations to Marketing Authorization
Variations to Marketing AuthorizationVariations to Marketing Authorization
Variations to Marketing AuthorizationMangesh Gawade
 
Common technical document format
Common technical document formatCommon technical document format
Common technical document formatDev Jain
 
ANVISA regulatory authority of brazil
ANVISA regulatory authority of brazilANVISA regulatory authority of brazil
ANVISA regulatory authority of brazilGaurav Kr
 
Pharmaceutical development report (pdr)
Pharmaceutical development report (pdr)Pharmaceutical development report (pdr)
Pharmaceutical development report (pdr)Atul Bhombe
 
Electronic submission PPT
Electronic submission PPTElectronic submission PPT
Electronic submission PPTDoninder Hooda
 
EU REGULATORY SUBMISSIONS
EU REGULATORY SUBMISSIONSEU REGULATORY SUBMISSIONS
EU REGULATORY SUBMISSIONSChandra Mohan
 
US and EU Submission – Comparative
US and EU Submission – ComparativeUS and EU Submission – Comparative
US and EU Submission – ComparativeGirish Swami
 
Comparison of Drug Approval Process in United States & Europe
Comparison of Drug Approval Process in United States & EuropeComparison of Drug Approval Process in United States & Europe
Comparison of Drug Approval Process in United States & EuropeChandra Mohan
 
EU Variations-Chandra.pptx
EU Variations-Chandra.pptxEU Variations-Chandra.pptx
EU Variations-Chandra.pptxChandra Mohan
 

La actualidad más candente (20)

Regulatory submission in Japan
Regulatory submission in JapanRegulatory submission in Japan
Regulatory submission in Japan
 
eCTD Submissions
eCTD SubmissionseCTD Submissions
eCTD Submissions
 
eCTD Submissions
eCTD SubmissionseCTD Submissions
eCTD Submissions
 
Electronic Submissions
Electronic SubmissionsElectronic Submissions
Electronic Submissions
 
NDA Application.pptx
NDA Application.pptxNDA Application.pptx
NDA Application.pptx
 
eCTD
eCTDeCTD
eCTD
 
A PRESENTATION ON DOSSIER.pptx
A PRESENTATION ON DOSSIER.pptxA PRESENTATION ON DOSSIER.pptx
A PRESENTATION ON DOSSIER.pptx
 
Variations to Marketing Authorization
Variations to Marketing AuthorizationVariations to Marketing Authorization
Variations to Marketing Authorization
 
Common technical document format
Common technical document formatCommon technical document format
Common technical document format
 
ANVISA regulatory authority of brazil
ANVISA regulatory authority of brazilANVISA regulatory authority of brazil
ANVISA regulatory authority of brazil
 
Pharmaceutical development report (pdr)
Pharmaceutical development report (pdr)Pharmaceutical development report (pdr)
Pharmaceutical development report (pdr)
 
Electronic submission PPT
Electronic submission PPTElectronic submission PPT
Electronic submission PPT
 
EU REGULATORY SUBMISSIONS
EU REGULATORY SUBMISSIONSEU REGULATORY SUBMISSIONS
EU REGULATORY SUBMISSIONS
 
E ctd specification_v3_2_2
E ctd specification_v3_2_2E ctd specification_v3_2_2
E ctd specification_v3_2_2
 
US and EU Submission – Comparative
US and EU Submission – ComparativeUS and EU Submission – Comparative
US and EU Submission – Comparative
 
Comparison of Drug Approval Process in United States & Europe
Comparison of Drug Approval Process in United States & EuropeComparison of Drug Approval Process in United States & Europe
Comparison of Drug Approval Process in United States & Europe
 
EU Variations-Chandra.pptx
EU Variations-Chandra.pptxEU Variations-Chandra.pptx
EU Variations-Chandra.pptx
 
DMF CEP
DMF CEPDMF CEP
DMF CEP
 
eCTD
eCTDeCTD
eCTD
 
Post-NOC changes
Post-NOC changesPost-NOC changes
Post-NOC changes
 

Destacado

EME2040 Project VI, Part III
EME2040 Project VI, Part IIIEME2040 Project VI, Part III
EME2040 Project VI, Part IIIJohn Hayes
 
Een therapie voor geluidsovergevoeligheid (Hyperacusis) en Tinnitus
Een therapie voor geluidsovergevoeligheid (Hyperacusis) en TinnitusEen therapie voor geluidsovergevoeligheid (Hyperacusis) en Tinnitus
Een therapie voor geluidsovergevoeligheid (Hyperacusis) en TinnitusRené Voortwist
 
Human Rights Abuses in China
Human Rights Abuses in ChinaHuman Rights Abuses in China
Human Rights Abuses in ChinaMerylBeth17
 
Vocabulary describing people
Vocabulary describing peopleVocabulary describing people
Vocabulary describing peoplejolehidy6
 
Stypendium z wyboru AnnaStroynowska
Stypendium z wyboru AnnaStroynowskaStypendium z wyboru AnnaStroynowska
Stypendium z wyboru AnnaStroynowskaAniaStr
 
Lawrence Family Townhouse
Lawrence Family TownhouseLawrence Family Townhouse
Lawrence Family Townhouselbridge89
 
Minden, ami szép(4) (nx power lite)+ani
Minden, ami szép(4) (nx power lite)+aniMinden, ami szép(4) (nx power lite)+ani
Minden, ami szép(4) (nx power lite)+aniVarganeAnny
 
MarcAtricK N5 j10t33
MarcAtricK N5 j10t33MarcAtricK N5 j10t33
MarcAtricK N5 j10t33MarcAtricK
 
Telford Apprentices 2006 07 Why should civil engineers address the Sustainabi...
Telford Apprentices 2006 07 Why should civil engineers address the Sustainabi...Telford Apprentices 2006 07 Why should civil engineers address the Sustainabi...
Telford Apprentices 2006 07 Why should civil engineers address the Sustainabi...katfyt
 
2011 Senior Executive Forum Final Presentation
2011 Senior Executive Forum   Final Presentation2011 Senior Executive Forum   Final Presentation
2011 Senior Executive Forum Final Presentationphil_waldeck
 
Ovjkvhbfguoghtjlvhfjvfbgugbu
OvjkvhbfguoghtjlvhfjvfbgugbuOvjkvhbfguoghtjlvhfjvfbgugbu
Ovjkvhbfguoghtjlvhfjvfbgugbuamber_smith
 
What's an RSS Feed? - A How-To for Blogging
What's an RSS Feed? - A How-To for BloggingWhat's an RSS Feed? - A How-To for Blogging
What's an RSS Feed? - A How-To for BloggingAstek Consulting
 
Presentation about leadership
Presentation about leadershipPresentation about leadership
Presentation about leadershipbvytis
 
10 may presentation_by_ahmed_abdel_latif
10 may presentation_by_ahmed_abdel_latif10 may presentation_by_ahmed_abdel_latif
10 may presentation_by_ahmed_abdel_latifJulien Grollier
 

Destacado (20)

EME2040 Project VI, Part III
EME2040 Project VI, Part IIIEME2040 Project VI, Part III
EME2040 Project VI, Part III
 
Rendorsegnek
RendorsegnekRendorsegnek
Rendorsegnek
 
Rafa unit 1
Rafa unit 1Rafa unit 1
Rafa unit 1
 
Een therapie voor geluidsovergevoeligheid (Hyperacusis) en Tinnitus
Een therapie voor geluidsovergevoeligheid (Hyperacusis) en TinnitusEen therapie voor geluidsovergevoeligheid (Hyperacusis) en Tinnitus
Een therapie voor geluidsovergevoeligheid (Hyperacusis) en Tinnitus
 
Start-up Battlefield in the Middle East
Start-up Battlefield in the Middle EastStart-up Battlefield in the Middle East
Start-up Battlefield in the Middle East
 
Human Rights Abuses in China
Human Rights Abuses in ChinaHuman Rights Abuses in China
Human Rights Abuses in China
 
Vocabulary describing people
Vocabulary describing peopleVocabulary describing people
Vocabulary describing people
 
Stypendium z wyboru AnnaStroynowska
Stypendium z wyboru AnnaStroynowskaStypendium z wyboru AnnaStroynowska
Stypendium z wyboru AnnaStroynowska
 
Lawrence Family Townhouse
Lawrence Family TownhouseLawrence Family Townhouse
Lawrence Family Townhouse
 
Minden, ami szép(4) (nx power lite)+ani
Minden, ami szép(4) (nx power lite)+aniMinden, ami szép(4) (nx power lite)+ani
Minden, ami szép(4) (nx power lite)+ani
 
MarcAtricK N5 j10t33
MarcAtricK N5 j10t33MarcAtricK N5 j10t33
MarcAtricK N5 j10t33
 
Telford Apprentices 2006 07 Why should civil engineers address the Sustainabi...
Telford Apprentices 2006 07 Why should civil engineers address the Sustainabi...Telford Apprentices 2006 07 Why should civil engineers address the Sustainabi...
Telford Apprentices 2006 07 Why should civil engineers address the Sustainabi...
 
Team Building
Team BuildingTeam Building
Team Building
 
2011 Senior Executive Forum Final Presentation
2011 Senior Executive Forum   Final Presentation2011 Senior Executive Forum   Final Presentation
2011 Senior Executive Forum Final Presentation
 
Ааия
АаияАаия
Ааия
 
Ovjkvhbfguoghtjlvhfjvfbgugbu
OvjkvhbfguoghtjlvhfjvfbgugbuOvjkvhbfguoghtjlvhfjvfbgugbu
Ovjkvhbfguoghtjlvhfjvfbgugbu
 
What's an RSS Feed? - A How-To for Blogging
What's an RSS Feed? - A How-To for BloggingWhat's an RSS Feed? - A How-To for Blogging
What's an RSS Feed? - A How-To for Blogging
 
Presentation about leadership
Presentation about leadershipPresentation about leadership
Presentation about leadership
 
感恩
感恩感恩
感恩
 
10 may presentation_by_ahmed_abdel_latif
10 may presentation_by_ahmed_abdel_latif10 may presentation_by_ahmed_abdel_latif
10 may presentation_by_ahmed_abdel_latif
 

Similar a Pros and cons of eCTD baseline submissions

eCTD in Australia and Experience in the Pilot Programme
eCTD in Australia and Experience in the Pilot ProgrammeeCTD in Australia and Experience in the Pilot Programme
eCTD in Australia and Experience in the Pilot ProgrammeTGA Australia
 
Ctd and ectd m pharmacy notes scop satara
Ctd and ectd  m pharmacy notes scop sataraCtd and ectd  m pharmacy notes scop satara
Ctd and ectd m pharmacy notes scop sataranikhil salunkhe
 
FDA Refused 510(k) Submissions
FDA Refused 510(k) SubmissionsFDA Refused 510(k) Submissions
FDA Refused 510(k) SubmissionsJoe Hage
 
Highlights from ExL Pharma's 2nd Leveraging Global eCTD Effciencies Conference
Highlights from ExL Pharma's 2nd Leveraging Global eCTD Effciencies ConferenceHighlights from ExL Pharma's 2nd Leveraging Global eCTD Effciencies Conference
Highlights from ExL Pharma's 2nd Leveraging Global eCTD Effciencies ConferenceExL Pharma
 
Presentation: eSubmissions in Australia - Part 1
Presentation: eSubmissions in Australia - Part 1Presentation: eSubmissions in Australia - Part 1
Presentation: eSubmissions in Australia - Part 1TGA Australia
 
TMF-Reference-Model-Presentation.pptx
TMF-Reference-Model-Presentation.pptxTMF-Reference-Model-Presentation.pptx
TMF-Reference-Model-Presentation.pptxJaimeHinojosa18
 
Common technical document (CTD) and electronic common technical document (eCTD)
Common technical document (CTD) and electronic common technical document (eCTD)Common technical document (CTD) and electronic common technical document (eCTD)
Common technical document (CTD) and electronic common technical document (eCTD)MOHAMMAD ASIM
 
Electronic submission requirements for prescription medicines - AU eCTD update
Electronic submission requirements for prescription medicines - AU eCTD updateElectronic submission requirements for prescription medicines - AU eCTD update
Electronic submission requirements for prescription medicines - AU eCTD updateTGA Australia
 
CTD AND ECTD IN QUALITY ASSURANCE BY INTHIYAZ RIPER
CTD AND ECTD IN QUALITY ASSURANCE BY INTHIYAZ RIPERCTD AND ECTD IN QUALITY ASSURANCE BY INTHIYAZ RIPER
CTD AND ECTD IN QUALITY ASSURANCE BY INTHIYAZ RIPERInthiyazBegum
 
CTD and eCTD - Common Technical Document
CTD and eCTD - Common Technical DocumentCTD and eCTD - Common Technical Document
CTD and eCTD - Common Technical DocumentDarewin Mendonsa
 
CTD and ECTD Document
CTD and ECTD Document CTD and ECTD Document
CTD and ECTD Document Nirmal Maurya
 
Regulatory Affairs role in Pharmaceutical Industry
Regulatory Affairs role in Pharmaceutical IndustryRegulatory Affairs role in Pharmaceutical Industry
Regulatory Affairs role in Pharmaceutical IndustryTarun Kumar Reddy
 
The Fast Track to Fair Lab Data
The Fast Track to Fair Lab Data The Fast Track to Fair Lab Data
The Fast Track to Fair Lab Data OSTHUS
 
Prodml Production Reporting | Hydrocarbon Allocation Forum | 2014 09-30
Prodml Production Reporting | Hydrocarbon Allocation Forum | 2014 09-30Prodml Production Reporting | Hydrocarbon Allocation Forum | 2014 09-30
Prodml Production Reporting | Hydrocarbon Allocation Forum | 2014 09-30EnergySys Limited
 
ctd and e ctd submission
ctd and e ctd submissionctd and e ctd submission
ctd and e ctd submissionRohit K.
 

Similar a Pros and cons of eCTD baseline submissions (20)

eCTD in Australia and Experience in the Pilot Programme
eCTD in Australia and Experience in the Pilot ProgrammeeCTD in Australia and Experience in the Pilot Programme
eCTD in Australia and Experience in the Pilot Programme
 
Ctd and ectd m pharmacy notes scop satara
Ctd and ectd  m pharmacy notes scop sataraCtd and ectd  m pharmacy notes scop satara
Ctd and ectd m pharmacy notes scop satara
 
FDA Refused 510(k) Submissions
FDA Refused 510(k) SubmissionsFDA Refused 510(k) Submissions
FDA Refused 510(k) Submissions
 
CTD & ECTD
CTD & ECTDCTD & ECTD
CTD & ECTD
 
Highlights from ExL Pharma's 2nd Leveraging Global eCTD Effciencies Conference
Highlights from ExL Pharma's 2nd Leveraging Global eCTD Effciencies ConferenceHighlights from ExL Pharma's 2nd Leveraging Global eCTD Effciencies Conference
Highlights from ExL Pharma's 2nd Leveraging Global eCTD Effciencies Conference
 
Presentation: eSubmissions in Australia - Part 1
Presentation: eSubmissions in Australia - Part 1Presentation: eSubmissions in Australia - Part 1
Presentation: eSubmissions in Australia - Part 1
 
TMF PDF.pdf
TMF PDF.pdfTMF PDF.pdf
TMF PDF.pdf
 
TMF-Reference-Model-Presentation.pptx
TMF-Reference-Model-Presentation.pptxTMF-Reference-Model-Presentation.pptx
TMF-Reference-Model-Presentation.pptx
 
CTD & E-CTD
CTD & E-CTDCTD & E-CTD
CTD & E-CTD
 
Common technical document (CTD) and electronic common technical document (eCTD)
Common technical document (CTD) and electronic common technical document (eCTD)Common technical document (CTD) and electronic common technical document (eCTD)
Common technical document (CTD) and electronic common technical document (eCTD)
 
Electronic submission requirements for prescription medicines - AU eCTD update
Electronic submission requirements for prescription medicines - AU eCTD updateElectronic submission requirements for prescription medicines - AU eCTD update
Electronic submission requirements for prescription medicines - AU eCTD update
 
ECTD BY NITESH
ECTD BY NITESHECTD BY NITESH
ECTD BY NITESH
 
CTD AND ECTD IN QUALITY ASSURANCE BY INTHIYAZ RIPER
CTD AND ECTD IN QUALITY ASSURANCE BY INTHIYAZ RIPERCTD AND ECTD IN QUALITY ASSURANCE BY INTHIYAZ RIPER
CTD AND ECTD IN QUALITY ASSURANCE BY INTHIYAZ RIPER
 
CTD and eCTD - Common Technical Document
CTD and eCTD - Common Technical DocumentCTD and eCTD - Common Technical Document
CTD and eCTD - Common Technical Document
 
CTD and eCTD.pptx
CTD and eCTD.pptxCTD and eCTD.pptx
CTD and eCTD.pptx
 
CTD and ECTD Document
CTD and ECTD Document CTD and ECTD Document
CTD and ECTD Document
 
Regulatory Affairs role in Pharmaceutical Industry
Regulatory Affairs role in Pharmaceutical IndustryRegulatory Affairs role in Pharmaceutical Industry
Regulatory Affairs role in Pharmaceutical Industry
 
The Fast Track to Fair Lab Data
The Fast Track to Fair Lab Data The Fast Track to Fair Lab Data
The Fast Track to Fair Lab Data
 
Prodml Production Reporting | Hydrocarbon Allocation Forum | 2014 09-30
Prodml Production Reporting | Hydrocarbon Allocation Forum | 2014 09-30Prodml Production Reporting | Hydrocarbon Allocation Forum | 2014 09-30
Prodml Production Reporting | Hydrocarbon Allocation Forum | 2014 09-30
 
ctd and e ctd submission
ctd and e ctd submissionctd and e ctd submission
ctd and e ctd submission
 

Más de eCTDconsultancy

Submitting electronic Drug Master Files (DMF) and Active Substance Master Fil...
Submitting electronic Drug Master Files (DMF) and Active Substance Master Fil...Submitting electronic Drug Master Files (DMF) and Active Substance Master Fil...
Submitting electronic Drug Master Files (DMF) and Active Substance Master Fil...eCTDconsultancy
 
IDMP value beyond compliance
IDMP value beyond complianceIDMP value beyond compliance
IDMP value beyond complianceeCTDconsultancy
 
IDMP and RIM: friend or foe?
IDMP and RIM: friend or foe?IDMP and RIM: friend or foe?
IDMP and RIM: friend or foe?eCTDconsultancy
 
Pharmacovigilance evmpd submission
Pharmacovigilance evmpd submissionPharmacovigilance evmpd submission
Pharmacovigilance evmpd submissioneCTDconsultancy
 
The Science of Submissions Part IA - The principles of the new variation regu...
The Science of Submissions Part IA - The principles of the new variation regu...The Science of Submissions Part IA - The principles of the new variation regu...
The Science of Submissions Part IA - The principles of the new variation regu...eCTDconsultancy
 
The Science of Submissions Part IB - How to handle grouping and worksharing i...
The Science of Submissions Part IB - How to handle grouping and worksharing i...The Science of Submissions Part IB - How to handle grouping and worksharing i...
The Science of Submissions Part IB - How to handle grouping and worksharing i...eCTDconsultancy
 

Más de eCTDconsultancy (6)

Submitting electronic Drug Master Files (DMF) and Active Substance Master Fil...
Submitting electronic Drug Master Files (DMF) and Active Substance Master Fil...Submitting electronic Drug Master Files (DMF) and Active Substance Master Fil...
Submitting electronic Drug Master Files (DMF) and Active Substance Master Fil...
 
IDMP value beyond compliance
IDMP value beyond complianceIDMP value beyond compliance
IDMP value beyond compliance
 
IDMP and RIM: friend or foe?
IDMP and RIM: friend or foe?IDMP and RIM: friend or foe?
IDMP and RIM: friend or foe?
 
Pharmacovigilance evmpd submission
Pharmacovigilance evmpd submissionPharmacovigilance evmpd submission
Pharmacovigilance evmpd submission
 
The Science of Submissions Part IA - The principles of the new variation regu...
The Science of Submissions Part IA - The principles of the new variation regu...The Science of Submissions Part IA - The principles of the new variation regu...
The Science of Submissions Part IA - The principles of the new variation regu...
 
The Science of Submissions Part IB - How to handle grouping and worksharing i...
The Science of Submissions Part IB - How to handle grouping and worksharing i...The Science of Submissions Part IB - How to handle grouping and worksharing i...
The Science of Submissions Part IB - How to handle grouping and worksharing i...
 

Último

20220816-EthicsGrade_Scorecard-JP_Morgan_Chase-Q2-63_57.pdf
20220816-EthicsGrade_Scorecard-JP_Morgan_Chase-Q2-63_57.pdf20220816-EthicsGrade_Scorecard-JP_Morgan_Chase-Q2-63_57.pdf
20220816-EthicsGrade_Scorecard-JP_Morgan_Chase-Q2-63_57.pdfChris Skinner
 
Pitch Deck Teardown: Xpanceo's $40M Seed deck
Pitch Deck Teardown: Xpanceo's $40M Seed deckPitch Deck Teardown: Xpanceo's $40M Seed deck
Pitch Deck Teardown: Xpanceo's $40M Seed deckHajeJanKamps
 
Lucia Ferretti, Lead Business Designer; Matteo Meschini, Business Designer @T...
Lucia Ferretti, Lead Business Designer; Matteo Meschini, Business Designer @T...Lucia Ferretti, Lead Business Designer; Matteo Meschini, Business Designer @T...
Lucia Ferretti, Lead Business Designer; Matteo Meschini, Business Designer @T...Associazione Digital Days
 
1911 Gold Corporate Presentation Apr 2024.pdf
1911 Gold Corporate Presentation Apr 2024.pdf1911 Gold Corporate Presentation Apr 2024.pdf
1911 Gold Corporate Presentation Apr 2024.pdfShaun Heinrichs
 
NAB Show Exhibitor List 2024 - Exhibitors Data
NAB Show Exhibitor List 2024 - Exhibitors DataNAB Show Exhibitor List 2024 - Exhibitors Data
NAB Show Exhibitor List 2024 - Exhibitors DataExhibitors Data
 
trending-flavors-and-ingredients-in-salty-snacks-us-2024_Redacted-V2.pdf
trending-flavors-and-ingredients-in-salty-snacks-us-2024_Redacted-V2.pdftrending-flavors-and-ingredients-in-salty-snacks-us-2024_Redacted-V2.pdf
trending-flavors-and-ingredients-in-salty-snacks-us-2024_Redacted-V2.pdfMintel Group
 
WSMM Technology February.March Newsletter_vF.pdf
WSMM Technology February.March Newsletter_vF.pdfWSMM Technology February.March Newsletter_vF.pdf
WSMM Technology February.March Newsletter_vF.pdfJamesConcepcion7
 
business environment micro environment macro environment.pptx
business environment micro environment macro environment.pptxbusiness environment micro environment macro environment.pptx
business environment micro environment macro environment.pptxShruti Mittal
 
Darshan Hiranandani [News About Next CEO].pdf
Darshan Hiranandani [News About Next CEO].pdfDarshan Hiranandani [News About Next CEO].pdf
Darshan Hiranandani [News About Next CEO].pdfShashank Mehta
 
The-Ethical-issues-ghhhhhhhhjof-Byjus.pptx
The-Ethical-issues-ghhhhhhhhjof-Byjus.pptxThe-Ethical-issues-ghhhhhhhhjof-Byjus.pptx
The-Ethical-issues-ghhhhhhhhjof-Byjus.pptxmbikashkanyari
 
BAILMENT & PLEDGE business law notes.pptx
BAILMENT & PLEDGE business law notes.pptxBAILMENT & PLEDGE business law notes.pptx
BAILMENT & PLEDGE business law notes.pptxran17april2001
 
EUDR Info Meeting Ethiopian coffee exporters
EUDR Info Meeting Ethiopian coffee exportersEUDR Info Meeting Ethiopian coffee exporters
EUDR Info Meeting Ethiopian coffee exportersPeter Horsten
 
Traction part 2 - EOS Model JAX Bridges.
Traction part 2 - EOS Model JAX Bridges.Traction part 2 - EOS Model JAX Bridges.
Traction part 2 - EOS Model JAX Bridges.Anamaria Contreras
 
Effective Strategies for Maximizing Your Profit When Selling Gold Jewelry
Effective Strategies for Maximizing Your Profit When Selling Gold JewelryEffective Strategies for Maximizing Your Profit When Selling Gold Jewelry
Effective Strategies for Maximizing Your Profit When Selling Gold JewelryWhittensFineJewelry1
 
Supercharge Your eCommerce Stores-acowebs
Supercharge Your eCommerce Stores-acowebsSupercharge Your eCommerce Stores-acowebs
Supercharge Your eCommerce Stores-acowebsGOKUL JS
 
1911 Gold Corporate Presentation Apr 2024.pdf
1911 Gold Corporate Presentation Apr 2024.pdf1911 Gold Corporate Presentation Apr 2024.pdf
1911 Gold Corporate Presentation Apr 2024.pdfShaun Heinrichs
 
WSMM Media and Entertainment Feb_March_Final.pdf
WSMM Media and Entertainment Feb_March_Final.pdfWSMM Media and Entertainment Feb_March_Final.pdf
WSMM Media and Entertainment Feb_March_Final.pdfJamesConcepcion7
 
Planetary and Vedic Yagyas Bring Positive Impacts in Life
Planetary and Vedic Yagyas Bring Positive Impacts in LifePlanetary and Vedic Yagyas Bring Positive Impacts in Life
Planetary and Vedic Yagyas Bring Positive Impacts in LifeBhavana Pujan Kendra
 

Último (20)

20220816-EthicsGrade_Scorecard-JP_Morgan_Chase-Q2-63_57.pdf
20220816-EthicsGrade_Scorecard-JP_Morgan_Chase-Q2-63_57.pdf20220816-EthicsGrade_Scorecard-JP_Morgan_Chase-Q2-63_57.pdf
20220816-EthicsGrade_Scorecard-JP_Morgan_Chase-Q2-63_57.pdf
 
Pitch Deck Teardown: Xpanceo's $40M Seed deck
Pitch Deck Teardown: Xpanceo's $40M Seed deckPitch Deck Teardown: Xpanceo's $40M Seed deck
Pitch Deck Teardown: Xpanceo's $40M Seed deck
 
Lucia Ferretti, Lead Business Designer; Matteo Meschini, Business Designer @T...
Lucia Ferretti, Lead Business Designer; Matteo Meschini, Business Designer @T...Lucia Ferretti, Lead Business Designer; Matteo Meschini, Business Designer @T...
Lucia Ferretti, Lead Business Designer; Matteo Meschini, Business Designer @T...
 
The Bizz Quiz-E-Summit-E-Cell-IITPatna.pptx
The Bizz Quiz-E-Summit-E-Cell-IITPatna.pptxThe Bizz Quiz-E-Summit-E-Cell-IITPatna.pptx
The Bizz Quiz-E-Summit-E-Cell-IITPatna.pptx
 
1911 Gold Corporate Presentation Apr 2024.pdf
1911 Gold Corporate Presentation Apr 2024.pdf1911 Gold Corporate Presentation Apr 2024.pdf
1911 Gold Corporate Presentation Apr 2024.pdf
 
NAB Show Exhibitor List 2024 - Exhibitors Data
NAB Show Exhibitor List 2024 - Exhibitors DataNAB Show Exhibitor List 2024 - Exhibitors Data
NAB Show Exhibitor List 2024 - Exhibitors Data
 
trending-flavors-and-ingredients-in-salty-snacks-us-2024_Redacted-V2.pdf
trending-flavors-and-ingredients-in-salty-snacks-us-2024_Redacted-V2.pdftrending-flavors-and-ingredients-in-salty-snacks-us-2024_Redacted-V2.pdf
trending-flavors-and-ingredients-in-salty-snacks-us-2024_Redacted-V2.pdf
 
WSMM Technology February.March Newsletter_vF.pdf
WSMM Technology February.March Newsletter_vF.pdfWSMM Technology February.March Newsletter_vF.pdf
WSMM Technology February.March Newsletter_vF.pdf
 
business environment micro environment macro environment.pptx
business environment micro environment macro environment.pptxbusiness environment micro environment macro environment.pptx
business environment micro environment macro environment.pptx
 
Darshan Hiranandani [News About Next CEO].pdf
Darshan Hiranandani [News About Next CEO].pdfDarshan Hiranandani [News About Next CEO].pdf
Darshan Hiranandani [News About Next CEO].pdf
 
The-Ethical-issues-ghhhhhhhhjof-Byjus.pptx
The-Ethical-issues-ghhhhhhhhjof-Byjus.pptxThe-Ethical-issues-ghhhhhhhhjof-Byjus.pptx
The-Ethical-issues-ghhhhhhhhjof-Byjus.pptx
 
BAILMENT & PLEDGE business law notes.pptx
BAILMENT & PLEDGE business law notes.pptxBAILMENT & PLEDGE business law notes.pptx
BAILMENT & PLEDGE business law notes.pptx
 
EUDR Info Meeting Ethiopian coffee exporters
EUDR Info Meeting Ethiopian coffee exportersEUDR Info Meeting Ethiopian coffee exporters
EUDR Info Meeting Ethiopian coffee exporters
 
WAM Corporate Presentation April 12 2024.pdf
WAM Corporate Presentation April 12 2024.pdfWAM Corporate Presentation April 12 2024.pdf
WAM Corporate Presentation April 12 2024.pdf
 
Traction part 2 - EOS Model JAX Bridges.
Traction part 2 - EOS Model JAX Bridges.Traction part 2 - EOS Model JAX Bridges.
Traction part 2 - EOS Model JAX Bridges.
 
Effective Strategies for Maximizing Your Profit When Selling Gold Jewelry
Effective Strategies for Maximizing Your Profit When Selling Gold JewelryEffective Strategies for Maximizing Your Profit When Selling Gold Jewelry
Effective Strategies for Maximizing Your Profit When Selling Gold Jewelry
 
Supercharge Your eCommerce Stores-acowebs
Supercharge Your eCommerce Stores-acowebsSupercharge Your eCommerce Stores-acowebs
Supercharge Your eCommerce Stores-acowebs
 
1911 Gold Corporate Presentation Apr 2024.pdf
1911 Gold Corporate Presentation Apr 2024.pdf1911 Gold Corporate Presentation Apr 2024.pdf
1911 Gold Corporate Presentation Apr 2024.pdf
 
WSMM Media and Entertainment Feb_March_Final.pdf
WSMM Media and Entertainment Feb_March_Final.pdfWSMM Media and Entertainment Feb_March_Final.pdf
WSMM Media and Entertainment Feb_March_Final.pdf
 
Planetary and Vedic Yagyas Bring Positive Impacts in Life
Planetary and Vedic Yagyas Bring Positive Impacts in LifePlanetary and Vedic Yagyas Bring Positive Impacts in Life
Planetary and Vedic Yagyas Bring Positive Impacts in Life
 

Pros and cons of eCTD baseline submissions

  • 1. Pros & cons of eCTD baseline submissions
  • 2. What is a baseline submission? Single eCTD submission capturing all the appropriate information that reflects what has been submitted oAll modules oModule 3 only (32S, 32P, 32A and/or 32R) Corresponds to approved marketing license of a drug Merges per eCTDs per strength to single eCTD lifecycle 20110920 Pros & cons of baseline submissions 2
  • 3. Content of a baseline Module 1 Cover letter (state content has not changed, only its format) Module 2 Integrated overviews and summaries for Quality, Nonclinical and Clinical or a clear combination of those Cumulative list of all clinical trials Individual study synopses Module 4 + 5 All study reports as is 20110920 Pros & cons of baseline submissions 3
  • 4. Content of a baseline Module 3 No chronological cumulative presentation, but a “current view” Hyperlinks not necessary Do not oExclude any information form original dossier (unless updated by a regulatory process) oInclude any information not submitted before in the original dossier Document granularity that fits best with the lifecycle of documents Granularity!? 20110920 Pros & cons of baseline submissions 4
  • 5. Document granularity Module 3 Coursest and finest granularity defined by ICH M4 on organisation of Module 3 Determine granularity based on likelihood of: Future changes Reusability across products Reusability across regions Apply meaningful names for now, here and the future Subsequent sequences should match granularity of the previous sequences 20110920 Pros & cons of baseline submissions 5
  • 6. Granularity and future? Only replace or delete whole documents, not sections or pages in eCTD e.g. single 32P33 vs. Formulation, filling, packaging and labelling Mention information only once and in a single document e.g. Batch numbering in 32P33 only and not repeated in 32P54 Do not mention the reason for submitting a document e.g. Do not mention “to support the change of.....” 20110920 Pros & cons of baseline submissions 6
  • 7. Granularity and regional difference Additional specifications beyond the Ph.Eur. in a subset of countries S41 Specifications Ph.Eur. Vs. S41 Specifications polymorphism Different level of detail in a limited number of documents e.g. Details around control of critical steps, whereas the remainder is identical 20110920 Pros & cons of baseline submissions 7
  • 8. Granularity and reuse across products Separate content from context Drug substance documentation not refering to the context of use Analytical procedures across substances and products P1 Description and composition vs. Container description P4 Compendial combined vs. Compendial individual P7 Container material information, rather usage 20110920 Pros & cons of baseline submissions 8
  • 9. How to define the granularity? By use of an ToC outline capturing granularity and naming Analytical procedure “Test C by Method D” is not product specific and can be reused across products 20110920 Pros & cons of baseline submissions 9
  • 10. When to be created and submitted? At start of an eCTD lifecycle for an existing dossier 0000=Baseline 0001=Major variation or renewal During the eCTD lifecycle 20110920 Pros & cons of baseline submissions 10
  • 11. Pros of baseline submissions Ability to remove repeating and therefore redundant information, such as Scale at other sections than S22 and P33 Manufacturer names at other sections than S21, P31 and A1 Buildings at other sections than A1 Ability to create content in context in appropriate sections Manufacturing process development and Pharmaceutical development Ability to apply specific information at relevant sections only In text and in header and footer 20110920 Pros & cons of baseline submissions 11
  • 12. Pros of baseline submissions 2 Ability to start a clear lifecycle and audit trail Ability to create documents for reuse across products, e.g. Filling, packaging and labelling processes Selection and justifications for excipients Suitability of container Excipients Analytical procedures (and Quality by design) Container closure systems Facilities and equipment 20110920 Pros & cons of baseline submissions 12
  • 13. Pros of baseline submissions 3 Greatly improves the review process Within the company For agencies Improves transparency What document has been submitted where? What products are supported by a document? EU agencies encourage/recommend baseline submissions; US accepts these 20110920 Pros & cons of baseline submissions 13
  • 14. Cons of baseline submissions Time consuming (up to 15 days) Requires limited content knowledge and advanced Word knowledge Insufficiencies and incompliance becomes apparent; e.g. Lack of validation because it got approved before it was required Lack of stability data because it was OK at time of registration Inability to Add more recent though never submitted information Correct erroneous information Remove out-dated though never replaced information 20110920 Pros & cons of baseline submissions 14

Notas del editor

  1. Slide is optioneel, wellicht niet nodig
  2. Suggestion bullit 1: Ability to relocate information to prevent repeating and therefore redundant information, such as